Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study

Journal of Vascular Surgery

Volumn 50, Issue 3, 2009, Pages 626-631

  Norman, Paul E ^a   Davis, Wendy A ^b   Coughlan, Melinda T ^c   Forbes, Josephine M ^c   Golledge, Jonathan ^d   Davis, Timothy M E ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CREATININE;

ABDOMINAL AORTA ANEURYSM; AGED; AMINO ACID BLOOD LEVEL; AORTA; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

AGED; AORTIC ANEURYSM, ABDOMINAL; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DOWN-REGULATION; HUMANS; LOGISTIC MODELS; LYSINE; MALE; MEN'S HEALTH; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; WESTERN AUSTRALIA;

EID: 68849129085     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.05.058     Document Type: Article

References (40)

1. Shteinberg D., Halak M., Shapiro S., Kinarty A., Sobol E., Lahat N., et al. Abdominal aortic aneurysm and aortic occlusive disaese: a comparison of risk factors and inflammatory response. Eur J Vasc Endovas Surg 20 (2000) 462-465
2. Blanchard J., Armenian H., and Friesen P. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol 151 (2000) 575-583
3. Lederle F.A., Johnson G.R., Wilson S.E., Chute E.P., Hye R.J., Makaroun M.S., et al. The aneurysm detection and management study screening program. Validation cohort and final results. Arch Int Med 160 (2000) 1425-1430
4. LaMorte W.W., Scott T.E., and Menzoian J.O. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: Relationship to cardiovascular risk factors. J Vasc Surg 21 (1995) 422-431
5. Singh K., Bonaa K.H., Jacobsen B.K., Bjork L., and Soldberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study. Am J Epidemiol 154 (2001) 236-244
6. Le M.T.Q., Jamrozik K., Davis T.M.E., and Norman P.E. Negative association between infra-renal aortic diameter and glycaemia: The Health In Men Study. Eur J Vasc Endovasc Surg 33 (2007) 599-604
7. Mattes E., Davis T.M.E., Yang D., Ridley D., Lund H., and Norman P.E. Prevalence of abdominal aortic aneurysms in men with diabetes. Med J Aust 166 (1997) 630-634
8. Jamrozik K., Norman P.E., Spencer C.A., Parsons R.W., Tuohy R., Lawrence-Brown M.M., et al. Screening for abdominal aortic aneurysms: lessons from a population-based study. Med J Aust 173 (2000) 345-350
9. Brady A.R., Thompson S.G., Fowkes G.R., Greenhalgh R.M., and Powell J.T. Abdominal aortic aneurysm expansion. Risk factors and time intervals for surveillance. Circulation 110 (2004) 16-21
10. Golledge J., Karan M., Moran C.S., Muller J., Clancy P., Dear A.E., et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 29 (2008) 665-672
11. Zieman S.J., and Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64 (2004) 459-470
12. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands L., and Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetology 29 (2008) 1-8
13. Jerums G., Panagiotopoulos S., Forbes J., Osicka T., and Cooper M. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch Biochem Biophys 419 (2003) 55-62
14. Norman P.E., Davis T.M.E., Le M., and Golledge J. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res 48 (2007) 125-131
15. Ahmed M.U., Thorpe S.R., and Baynes J.W. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261 (1986) 4889-4894
16. Kilhovd B.K., Berg T.J., Birkeland K.I., Thorsby P., and Hanssen K.F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22 (1999) 1543-1548
17. Semba R.D., Najjar S.S., Sun K., and Lakatta EG L.F. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 22 (2009) 74-79
18. Norman P.E., Jamrozik K., Lawrence-Brown M.M., Le M., Spencer C.A., Tuohy R., et al. Population-based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 329 (2004) 1259-1262
19. Norman P.E., Flicker L., Almeida O.P., Hankey G.J., Hyde Z., and Jamrozik K. Cohort profile: The Health In Men Study (HIMS). Int J Epidemiol 38 (2008) 48-52
20. Leng G., and Fowkes F. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 45 (1992) 1101-1109
21. Norman P.E., Spencer C.A., Lawrence-Brown M.M., and Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 110 (2004) 862-866
22. Norman P.E., Le M.T.Q., Pearce C., and Jamrozik K. Infra-renal aortic diameter predicts all-cause mortality. Arterioscler Thromb Vasc Biol 24 (2004) 1278-1282
23. Coughlan M.T., Thallas-Bonke V., Pete J., Long D.M., Gasser A., Tong D.C., et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. Endocrinology 148 (2007) 886-895
24. Oldfield M.D., Bach L.A., Forbes J.M., Nikolic-Paterson D., McRobert A., Thallas V., et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108 (2001) 1853-1863
25. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
26. Thompson R.W., Holmes D.R., Mertens R.A., Liao S., Botney M.D., Mecham R.P., et al. Production and localisation of 92-kilodalton gelatinase in abdominal aortic aneurysms. J Clin Invest 96 (1995) 318-326
27. Golledge J., Muller J., Daugherty A., and Norman P.E. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 26 (2006) 2605-2613
28. Mauer S. Structural-functional correlations of diabetic nephropathy. Kidney Int 45 (1994) 612-622
29. Murphy M., Godson C., Cannon S., Kato S., Mackenzie H.S., Martin F., et al. Suppression subtraction hybridization identiefies high glucose levels as a stimulus for expression of Connective Tissue Growth Factor and other genes in human mesangial cells. J Biol Chem 274 (1999) 5830-5834
30. McLennan S., Fisher E., Martell S., Death A., Williams P., Lyons J., et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int 58 (2000) S81-S7
31. Astrand H., Ryden-Ahlgren A., Sundkvist G., Sandgren T., and Lanne T. Reduced aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg 33 (2007) 592-598
32. Sonesson B., Hansen F., Stale H., and Lanne T. Compliance and diameter in the human abdominal aorta - the influence of sex and age. Eur J Vasc Surg 7 (1993) 690-697
33. Winlove C.P., Parker K.H., Avery N.C., and Bailey A.J. Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 39 (1996) 1131-1139
34. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertension 21 (2003) 3-12
35. Kim Y.S., Kim B.C., Song C.Y., Hong H.K., Moon K.C., and Lee H.S. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med 138 (2001) 59-68
36. Brunelli T., Prisco D., Fedi S., Rogolino A., Farsi A., and Pepe G. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg 32 (2000) 531-536
37. Wollesen F., Brattstrom L., Refsum H., Ueland P.M., Berglund L., and Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55 (1999) 1028-1035
38. Miura J., Yamagishi S., Uchigata Y., Takeuchi M., Yamamoto H., Makita Z., et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complicat 17 (2003) 16-21
39. Jandeleit-Dahm K.A., Lassila M., and Allen T.J. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann N Y Acad Sci 1043 (2005) 759-766
40. Bakris G.L., Bank A.J., Kass D.A., Neutel J.M., Preston R.A., and Oparil S. Advanced glycation end-product cross-link breakers. Am J Hypertension 17 (2004) 23S-30S